Please select your view
Dr Travis Brown obtained his MBBS from the Australian National University (ANU) in Canberra. After completing two years as a junior doctor at St Vincent Hospital in Melbourne, he undertook Anatomical Pathology training at Ballarat Base Hospital and the Royal Melbourne Hospital before transferring to General Pathology Specialty training with Healthscope Pathology (now Australian Clinical Labs) in Clayton, Melbourne.
He also completed a Bachelor of Science (Medical Sciences) at La Trobe University in Melbourne before entering graduate entry medicine at Canberra. Travis completed General Pathology Specialty training in November 2016 and is currently working in Wayville, Adelaide with Australian Clinical Labs. He enjoys the diversity that General Pathology provides working in biochemistry, microbiology, haematology and anatomical pathology. Travis also has a special interest in Information Technology and Pathology informatics.
Dr Jayasinghe joined Healthscope Pathology in 2012. Having completed her specialist training and MD in Histopathology in Sri Lanka, Dr Jayasinghe moved to Australia. She trained as an Anatomical Pathology Registrar rotating through Monash Medical Centre and Peter MacCallum Cancer Centre. After obtaining her FRCPA in 2011, Dr Jayasinghe worked as an Anatomical Pathologist at the Royal Women's Hospital, Melbourne before joining Healthscope Pathology at The Northern Hospital. While she enjoys the whole variety of her histopathology and cytopathology work, her special interests are in breast and gynaecological pathology.
Professor O’Toole is recognised as one of Australia’s leading molecular pathologists, with major research and diagnostic interests in breast cancer as well as the molecular pathology of melanoma and lung cancer. She was an expert member of the working group for Cancer Australia on Influencing Best Practice in Breast Cancer and is a National Breast Cancer Foundation Practitioner Fellow.
Professor O’Toole is Clinical Professor at Sydney Medical School and head of Breast Cancer Translational Research at the Garvan Institute of Medical Research where she collaborates with researchers and clinicians nationally and internationally to promote the rapid translation of scientific discoveries. Her work has appeared in more than 100 scientific publications and she has secured over $20 million in research funding as a chief investigator. She is Chair of Cancer Services for the Royal College of Pathologists of Australasia.
Her areas of interest include Molecular Pathology, Breast Pathology and GIT/Hepatobiliary Pathology. She is FRCPA and holds MB, BS (Hons I and the University Medal), BSc Med (Hons I and recipient of the Prize for Experimental Pathology) and a PhD.
Dr Mirette Saad is a Chemical Pathologist and the National Clinical Director of the Molecular Genetic Pathology at Australian Clinical Labs.
Dr Saad’s current professional interests are continuing development in Molecular Genetics and Chemistry. In addition to her daily work to provide a comprehensive Chemical Pathology testing service, she currently medically supervises the Molecular Genetic testing for non-invasive prenatal testing (NIPT), hereditary disorders, personalised drug therapy and cancer. She is working closely with Health Practitioners and the laboratory team to employ the knowledge and identify opportunities to provide the best diagnostic services which include interpretation of results and the provision of important consultative advice to doctors in assisting with the management plans of patients.
Healthy workers = healthy organisations = healthy business performance. There is a wealth of emerging evidence highlighting the success of health and wellbeing programs, and the return on investment received by businesses.
Lead poisoning can sometimes be a fatal condition and usually occurs over a period of months or years. Screen for it today by a simple blood test.
Alcohol use can have a number of adverse impacts on workplaces, how will you implement your plan?
Hepatitis A virus infection can take between 15 to 50 days to develop following exposure to the virus.